Mr. John Suk Joins Covalon’s Board of Directors

Mr. Suk is an experienced executive within Canada’s pharmaceutical and healthcare industries. After holding senior executive roles at McNeil Labs (Johnson & Johnson), GlaxoSmithKline plc, and Hoffman La Roche, Mr. Suk founded, in 1997, Byk Canada (later known as Nycomed), a subsidiary of German company Byk Gulden. In the fourteen years Mr. Suk served as President and CEO of Nycomed, the company’s sales reached over $300 million. From 2006 to 2017, Mr. Suk served on the Board of Trustees of Brock University and was Chair of The Board from 2013 through 2016. He has also served on the Boards of Canada’s Research-Based Pharmaceutical Companies, the Health Research Foundation, Innovate Niagara, IIX Technologies, Medical Futures, and Exciton Technologies. Mr. Suk holds an H.B.Sc from Brock University, an Advanced Management Certificate from Insead and the professional ICD.D designation from Rotman School of Management at the University of Toronto.

“I deeply appreciate the value of healthcare innovation emanating from Covalon’s talented R&D lab and am therefore honoured to serve on the Board,” said Mr. Suk. “Covalon has succeeded in extremely competitive international markets and I see many further opportunities for growth in the coming years. I look forward to contributing and being part of Covalon’s continued success.”

“I am delighted to have Mr. Suk join Covalon’s Board of Directors,” said Brian Pedlar, Chief Executive Officer. “Mr. Suk’s remarkable career in the healthcare industry is incredibly advantageous for us as we look forward to many years of growth at Covalon. We place tremendous value on the experience of our Directors, and are excited that Mr. Suk’s considerable talents will be put to use by Covalon.”

Mr. Suk’s appointment to Covalon’s Board of Directors is subject to TSX approval.

About Covalon
Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon’s patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon’s technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan, “estimate”, “expect”, “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company’s ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190130005009/en/